Product Images Entresto
View Photos of Packaging, Labels & Appearance
- 71610-806-32 - 71610 806 32
- Aphena - Aphena
- Valsartan structural formula - ENTRESTO 01
- Figure 1: Effect of ENTRESTO on Pharmacokinetics of Coadministered Drugs - ENTRESTO 02
- Figure 2: Pharmacokinetics of ENTRESTO in Specific Populations - ENTRESTO 03
- Figure 3: Kaplan-Meier Curves for the Primary Composite Endpoint (A), Cardiovascular Death (B), and Heart Failure Hospitalization (C) - ENTRESTO 04
- Figure 4: Primary Composite Endpoint (CV Death or HF Hospitalization) - Subgroup Analysis - ENTRESTO 05
- Figure 5: Mean Number of Events Over Time for the Primary Composite Endpoint of Total HF Hospitalizations and CV Death - ENTRESTO 09
- Figure 6: Primary Composite Endpoint of Total HF Hospitalizations and CV Death – Subgroup Analysis (PARAGON-HF) - ENTRESTO 10
- Figure 7: Treatment Effect for the Composite Endpoint of Time to First HF Hospitalization or CV Death by LVEF in PARADIGM-HF and PARAGON-HF - ENTRESTO 11
Product Label Images
The following 10 images provide visual information about the product associated with Entresto NDC 71610-806 by Aphena Pharma Solutions - Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
71610-806-32 - 71610 806 32
This text appears to be a description of a medication called Sacubitril/Valsartan (Entresto), with references to NDC# 71610.606-32 and Batch:0. It seems to provide information related to prescription or dosage of the medication.*
Aphena - Aphena
Valsartan structural formula - ENTRESTO 01
Figure 1: Effect of ENTRESTO on Pharmacokinetics of Coadministered Drugs - ENTRESTO 02
This text provides information about the geometric mean ratio and 90% confidence interval of coadministered drugs such as Furosemide, Warfarin, Digoxin, Carvedilol, Levonorgestrel, Ethinyl estradiol, Amlodipine, HCTZ, Metformin, Atorvastatin, and Sildenafil. It also indicates a change relative to reference.*
Figure 2: Pharmacokinetics of ENTRESTO in Specific Populations - ENTRESTO 03
Figure 3: Kaplan-Meier Curves for the Primary Composite Endpoint (A), Cardiovascular Death (B), and Heart Failure Hospitalization (C) - ENTRESTO 04
Figure 4: Primary Composite Endpoint (CV Death or HF Hospitalization) - Subgroup Analysis - ENTRESTO 05
This information provides a detailed breakdown of demographic and clinical characteristics of a population, including age, gender, weight, race, region, medical conditions (e.g., heart failure, diabetes, hypertension), medications (ENTRESTO and Enalapril), and outcomes (Hazard Ratio). The data is organized in a table format showing percentages within each subgroup, helping to identify trends and patterns among different variables in the study population.*
Figure 5: Mean Number of Events Over Time for the Primary Composite Endpoint of Total HF Hospitalizations and CV Death - ENTRESTO 09
Figure 6: Primary Composite Endpoint of Total HF Hospitalizations and CV Death – Subgroup Analysis (PARAGON-HF) - ENTRESTO 10
Figure 7: Treatment Effect for the Composite Endpoint of Time to First HF Hospitalization or CV Death by LVEF in PARADIGM-HF and PARAGON-HF - ENTRESTO 11
This text provides a comparison of hazard ratios for the PARADIGM-HF and PARAGON-HF trials, specifically comparing ENTRESTO versus enalapril and ENTRESTO versus valsartan. It also displays left ventricular ejection fraction percentages at the screening stage.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
